Phaseline

Companies › Shanghai Ruiliyuan Biotechnology

Shanghai Ruiliyuan Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HRYZ-T102 TCR-T Cell
AFP-specific T cell receptor (TCR) engineered T cells
AFPPhase 1Hepatic Cell CarcinomaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06515314HRYZ-T102 TCR-T CellPhase 1Hepatic Cell CarcinomaOncologyAug 2027

Targets

AFP (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.